Vaginal microbiota impacts of a Lactobacillus crispatus live biotherapeutic and predictors of colonization in randomized controlled trial

Seth M. Bloom, Laura Symul, Joseph Elsherbin, Jiawu Xu, Salina Hussain and , E.A.
Additional contact information
Laura Symul: Université catholique de Louvain, LIDAM/ISBA, Belgium

No 2026029, LIDAM Reprints ISBA from Université catholique de Louvain, Institute of Statistics, Biostatistics and Actuarial Sciences (ISBA)

Abstract: Bacterial vaginosis (BV) affects >25% of women worldwide and often recurs after standard-of-care metronidazole (MTZ) treatment. LACTIN-V, a live biotherapeutic product (LBP) containing Lactobacillus crispatus strain CTV-05, significantly reduced recurrent BV in a phase 2b clinical trial, but efficacy was incomplete. Here, we characterize microbiota and immune effects using multi-omics and define correlates of treatment success. By week 12, an L. crispatus-dominant microbiota was achieved in 30% of LBP recipients compared with 9% of placebo recipients (benefit ratio: 3.31; p

Keywords: Vaginal microbiome; live biotherapeutic product; bacterial vaginosis; women’s health; Lactobacillus (search for similar items in EconPapers)
Pages: 28
Date: 2026-04-08
Note: In: Cell Host & Microbe, vol. 34(4), p. 734-750
References: Add references at CitEc
Citations:

Downloads: (external link)
https://research.dial.uclouvain.be/

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:aiz:louvar:2026029

DOI: 10.1016/j.chom.2026.03.003

Access Statistics for this paper

More papers in LIDAM Reprints ISBA from Université catholique de Louvain, Institute of Statistics, Biostatistics and Actuarial Sciences (ISBA) Voie du Roman Pays 20, 1348 Louvain-la-Neuve (Belgium). Contact information at EDIRC.
Bibliographic data for series maintained by Alain Gillis ().